Acute Coronary Syndromes
7 COMMENT S - Feb 6, 2012 09:15 EST
Dr David Cohen points out some of physicians' potential "psychological" barriers to more rapid adoption of new antiplatelet agents, even though they may be the best choice for their patients.

Washington, DC - Adoption of new antiplatelet agents such as ticagrelor (Brilinta/Brilique, AstraZeneca) and prasugrel (Effient, Lilly/Daiichi-Sanyo) for ACS patients has been slow so far because many doctors have not properly understood the bleeding-thrombosis trade-off, Dr David Cohen (St Luke's Mid America Heart Institute, Kansas City, MO) explained here at CRT 2012, the Cardiovascular Research Technologies conference [1].

During a session on antiplatelet drugs for ACS, Dr Michael Gibson (Beth Israel Deaconess, Boston, MA) mentioned that in the first five months since the FDA approved ticagrelor, only 1700 prescriptions for the drug have been written. "That's pretty slow," Cohen remarked, especially compared with the relatively rapid uptake of clopidogrel in the late 1990s as a safer alternative to ticlopidine.
Read full article »


Acute Coronary Syndromes
Feb 7, 2012 12:20 EST


Editorial programs
Debate and dialogue between top cardiovascular specialists, produced by
theheart.org's editorial team
View all »
The Heart of a Woman
The Heart of a Woman
2 COMMENTS - Apr 27, 2009 13:25 EDT